Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

BioNTech SE

BNTX
Current price
94.1 USD -3.62 USD (-3.70%)
Last closed 96.95 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 23 363 979 264 USD
Yield for 12 month -9.82 %
1Y
3Y
5Y
10Y
15Y
BNTX
21.11.2021 - 28.11.2021

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany. Address: An der Goldgrube 12, Mainz, Germany, 55131

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

116.2 USD

P/E ratio

193.9

Dividend Yield

Current Year

+4 153 673 973 USD

Last Year

+18 827 595 883 USD

Current Quarter

+204 040 125 USD

Last Quarter

+1 608 610 580 USD

Current Year

+3 501 311 143 USD

Last Year

+13 898 438 919 USD

Current Quarter

+139 760 960 USD

Last Quarter

+1 413 815 344 USD

Key Figures BNTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -46 900 000 USD
Operating Margin TTM -270.36 %
PE Ratio 193.9
Return On Assets TTM -0.54 %
PEG Ratio 0.0449
Return On Equity TTM 0.56 %
Wall Street Target Price 116.2 USD
Revenue TTM 2 729 600 000 USD
Book Value 84 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -85.3 %
Dividend Yield
Gross Profit TTM 16 065 200 000 USD
Earnings per share 0.5 USD
Diluted Eps TTM 0.5 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY -79.5 %
Profit Margin 4.14 %

Dividend Analytics BNTX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BNTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date 02.06.2022
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date 17.06.2022

Stock Valuation BNTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 193.9
Forward PE 7.0373
Enterprise Value Revenue 0.8706
Price Sales TTM 5.4571
Enterprise Value EBITDA 3.057
Price Book MRQ 0.9584

Financials BNTX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BNTX

For 52 weeks

85.21 USD 125.83 USD
50 Day MA 90.92 USD
Shares Short Prior Month 3 691 199
200 Day MA 99.52 USD
Short Ratio 5.93
Shares Short 3 424 249
Short Percent 6.69 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

430.32 USD Microsoft Corporation +0.69 (+0.16%)
Detailed analytics

ETF funds


S

SX7EEX

14.75 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics